What is the Brexpiprazole?

Brexpiprazole is , while it's Molecular Formula is C 25 H 27 N 3 O 2 S. Brexpiprazole is a drug candidate useful in treatment and prevention of mental disorders including CNS disorders.

What is the CAS number for Brexpiprazole?

The CAS number of Brexpiprazole is 913611-97-9.

What is Brexpiprazole (913611-97-9) used for?

Brexpiprazole is a novelantipsychotic drug which serves as a serotonin ? dopamineactivity modulator and has demonstrated efficacy as anadjunctive treatment in patients with major depressive disorder(MDD). The drug exhibits a unique pharmacological profile,acting as a partial agonist of serotonin 5-HT1A and dopamineD2 receptors and as a full antagonist of 5-HT2A andnoradrenaline α1B/2C receptors, with similar subnanomolarbinding affinity. The drug, which was developed by Otsukaand Lundbeck, was approved in 2015 by the FDA for thetreatment of schizophrenia and as an adjunctive treatment fordepression. Brexpiprazole is widely considered to be asuccessor to Otsuka’s antipsychotic drug aripiprazole (tradename Abilify) whose patent expired in August 2014.

Product Class

913611-97-9

Product Name：Brexpiprazole
Molecular Formula：C₂₅H₂₇N₃O₂S
Purity：99%
Molecular Weight：433.574

Inquiry

Product Details:

CasNo： 913611-97-9

Molecular Formula： C₂₅H₂₇N₃O₂S

Buy Reliable Quality Brexpiprazole,99% Pure 913611-97-9 In Stock

Molecular Formula:C₂₅H₂₇N₃O₂S
Molecular Weight:433.574
Melting Point:179 - 181oC
Boiling Point:675.2±55.0 °C(Predicted)
PKA:11.22±0.70(Predicted)
Density:1.245±0.06 g/cm3(Predicted)

Brexpiprazole(Cas 913611-97-9) Usage

Overview	Brexpiprazole is an atypical antipsychotic medication primarily used to treat mental health conditions such as schizophrenia and major depressive disorder (MDD).
Uses	Clinical studies have demonstrated the efficacy of brexpiprazole in improving overall symptomatology and psychosocial functioning in adults with acute exacerbation of schizophrenia. As a maintenance treatment, brexpiprazole has shown to delay the time to relapse and stabilize or continue to improve symptoms and functioning in patients already stabilized on the drug.
Mechanism of Action	Brexpiprazole exerts its therapeutic effects by acting on various neurotransmitter receptors in the brain. It has high affinity for serotonin (5-HT) 1A and 2A receptors, dopamine (D) 2 receptors, and α1B and α2C adrenergic receptors. It displays partial agonism at 5-HT1A and D2 receptors and potent antagonism at 5-HT2A and α1B,2C adrenergic receptors. It also exhibits affinity for D3, 5-HT2B, 5-HT7, and α1A,1D receptors, as well as moderate affinity for histamine (H1) receptors and low affinity for muscarinic (M1) receptors.

913611-97-9 Relevant articles

Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial

Christoph U. Correll, M.D., Aleksandar Skuban, M.D., John Ouyang, Ph.D., Mary Hobart, Ph.D., Stephanie Pfister, M.A., M.B.A., Robert D. McQuade, Ph.D., Margaretta Nyilas, M.D., William H. Carson, M.D., Raymond Sanchez, M.D., Hans Eriksson, M.D.

American Journal of Psychiatry, 16 Apr 2015

This was a multicenter, randomized, double-blind, placebo-controlled study. Patients with schizophrenia experiencing an acute exacerbation were randomly assigned to daily brexpiprazole at a dosage of 0.25, 2, or 4 mg or placebo (1:2:2:2) for 6 weeks. Outcomes included change from baseline to week 6 in Positive and Negative Syndrome Scale (PANSS) total score (primary endpoint measure), Clinical Global Impressions Scale (CGI) severity score (key secondary endpoint measure), and other efficacy and tolerability measures.

Large-steric-hindrance N-heterocyclic carbene palladium complex, preparation method and application thereof, and synthesis method of sonidegib based on large-steric-hindrance N-heterocyclic carbene palladium complex

-

Paragraph 0195; 0208-0210, (2021/01/24)

The invention belongs to the technical f...

Brexpiprazole I: In Vitro and In Vivo Characterization of a Novel Serotonin-Dopamine Activity Modulator

Kenji Maeda, Haruhiko Sugino, Hitomi Akazawa, Naoki Amada, Jun Shimada, Takashi Futamura, Hiroshi Yamashita, Nobuaki Ito, Robert D. McQuade, Arne Mørk, Alan L. Pehrson, Morten Hentzer, Vibeke Nielsen, Christoffer Bundgaard, Jørn Arnt, Tine Bryan Stensbøl and Tetsuro Kikuchi

, Journal of Pharmacology and Experimental Therapeutics September 2014, 350 (3) 589-604;

Brexpiprazole inhibited DOI (2,5-dimethoxy-4-iodoamphetamine)-induced head twitches in rats, suggestive of 5-HT2A antagonism. Furthermore, in vivo D2 partial agonist activity of brexpiprazole was confirmed by its inhibitory effect on reserpine-induced DOPA accumulation in rats.

913611-97-9 Upstream products

913613-82-8
7-(4-chlorobutoxy)quinoline-2(1H)-one
1677681-05-8
1-(benzo[b]thiophen-4-yl)piperazine hydrochloride
70500-72-0
7-hydroxy-1H-quinolin-2-one
66490-33-3
4-chlorobenzothiophene

913611-97-9 Downstream products

1427046-45-4
carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester 4-nitrophenyl ester
1427049-01-1
7-[4-(4-benzo[b]thiophene-4-yl-piperazin-1-yl)butoxy]quinolin-2-yloxymethyl cyclohexyl carbonate
1427049-18-0
carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester cyclohexyl ester hydrochloride
1427044-88-9
7-[4-(4-benzo[b]thiophene-4-ylpiperazin-1-yl)butoxy]-2-benzyloxymethoxyquinoline

Relevant Products

Sparsentan
CAS：254740-64-2
Abiraterone Acetate
CAS：154229-18-2
Ciclopirox
CAS：29342-05-0